
About Vaxart
Vaxart is a publicly listed company based in San Francisco (United States) founded in 2004. Developer of therapeutic solutions for treating multiple infectious diseases. Vaxart has raised $57.97 million across 11 funding rounds from investors including HHS, Care Capital Management and Care Capital. The company has 115 employees. Vaxart offers products and services including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is Vaxart Inc. Its competitors include Adaptive Biotechnologies, Moderna and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2004 and based in San Francisco, United States, oral vaccines targeting infectious diseases are developed by Vaxart within the biotechnology sector. A proprietary delivery platform is employed to produce recombinant vaccines, with the pipeline covering seasonal influenza, norovirus, RSV, HSV-2, avian influenza, and Ebola. Vaccines addressing influenza treatment are also included in the offerings.
- Headquarters San Francisco, United States
- Employees 115
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website vaxart.com
- Social LinkedIn
- Legal Name Vaxart, Inc.
- Annual Revenue$237.26 M (USD)726.68as on Dec 31, 2025
- Net Profit$16.33 M (USD)as on Dec 31, 2025
- EBITDA$26.65 M (USD)as on Dec 31, 2025
- Total Equity Funding$57.97M (USD)
in 11 rounds
- Latest Funding Round$18.4M (USD), Series C
Jan 2015
- InvestorsHHS
& 5 more
- Employee Count115
Products & Services of Vaxart
Vaxart offers a comprehensive portfolio of products and services, including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.
Vaccines delivered as oral pills for immunity against viral diseases.
Platform for developing oral recombinant vaccines.
Platform focused on enhancing mucosal immune responses.
Funding Insights of Vaxart
Vaxart has successfully raised a total of $57.97M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $18.4 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $57.97M
- Total Rounds 11
- Last Round Series C β $18.4M
- First Round $2.78M
(Apr 2007)
- Investors Count 6
Latest 10 of 11 funding rounds of Vaxart with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2015 | $18.4M | Series C | β | Care Capital Management | β |
| Aug 2013 | $20M | Series C | β | β | β |
| Jun 2012 | $16.87M | Series B | β | Care Capital, Quantum Technology Partners | β |
| Sep 2009 | $1.25M | Grant | β | β | |
| Aug 2009 | $2.78M | Grant | β | β | |
| Jul 2009 | $340,505 | Grant | β | β | |
| Aug 2008 | $340,505 | Grant | β | β | |
| Jul 2008 | $340,505 | Grant | β | β | |
| Nov 2007 | $2.7M | Series A | β | Quantum Technology Partners, Life Science Angels | β |
| Nov 2007 | $600,000 | Grant | β | β |
6 investors in total: 6 institutional.
Investors in Vaxart
Vaxart has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Care Capital Management and Care Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| carecapital.com | ||||
| quantumtp.com | ||||
Life sciences startups are funded by a non-profit angel network. | lifescienceangels.com | Sunnyvale, United States | ||
| sbir.nih.gov | ||||
| carecapitalmanagement.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Vaxart
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vaxart
60 people are tracked at Vaxart (20 in leadership, 18 in board & advisors, 22 in team); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Jon Lindbloom | Director Of Technical Operations | Leadership |
Laurie Hastings | Vice President Human Resources | Leadership |
Becca Flitter | Director Of Immunology | Leadership |
James F. Cummings | Chief Medical Officer | Leadership |
Malik Rafi | Vice President, Manufacturing | Leadership |
Dana Opas | Director, Clinical Program Management | Leadership |
Maria Apkarian | Vice President Clinical Operations | Leadership |
Nicholas D’Amato | Director, Clinical Operations | Leadership |
Gargi Choudhary | Vice President, Analytical Development | Leadership |
Steven Lo | CEO | Leadership |
Sean Tucker | SVP & Chief Scientific Officer | Leadership |
Molly Braun | Associate Director, Immunology | Leadership |
James Lay | Vice President Information Technology | Leadership |
Raymond D. Stapleton | Chief Technology Officer | Leadership |
Vu Tran | Director Of Drug Product | Leadership |
William Sun | Senior Director | Leadership |
Emilia Bora | Director, Analytical Development | Leadership |
Jerlisa Ann Arizala | Associate Director | Leadership |
Pam de Moor | Vice President, Formulations | Leadership |
Gina Mastrosimone | Vice President, Business Strategy And Planning | Leadership |
40 more people are available in the full profile.
Complete people profiles for Vaxart
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vaxart
Vaxart is a publicly listed company on the OTC with ticker symbol VXRT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Feb 2018
- Listed onNASDAQ: VXRT
- Listed entityVaxart, Inc.
- Exchange sectorHealth technology
- ISINUS92243A2006
- Share price$0.46 (+3.8% on the day) · 2026-10-13
- Market capitalisation$110.9M
- Price to earnings2.9
- EPS (diluted, trailing year)$0.16
- Volume (last session)329,050
Financials of Vaxart
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $237.3M | $16.3M | $26.6M |
| 2024 | $28.7M | -$67.0M | -$61.9M |
| 2023 | $7.4M | -$82.5M | -$78.8M |
| 2022 | $107,000 | -$107.8M | -$107.1M |
| 2021 | $892,000 | -$70.5M | -$67.3M |
Detailed financial statements for Vaxart
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vaxart
4 dated milestones of Vaxart across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Vaxart is founded.
- Funding First funding round of $2.8M.
- Funding Latest funding round, Series C, of $18.4M.
- IPO Lists on the stock exchange (IPO).
Competitors of Vaxart
Vaxart has 3 listed competitors in our database, 3 of them funded. They include Adaptive Biotechnologies, Moderna and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of Vaxart
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vaxart
The website of Vaxart (vaxart.com) receives about 4.8K visits a month and ranks #4,483,544 among all websites worldwide, #5,417 in Biotechnology and Pharmaceuticals.
- Monthly visits4.8K
▲ 20.1% vs previous month
- Unique visitors1.6K
per month
- Global rank#4,483,544
among all websites
- Category rank#5,417
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.7
- Average visit23 sec
- DevicesDesktop 37% Β· Mobile 63%
Websites whose visitors overlap most with Vaxart. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
sanofipasteur.com | sanofipasteur.com | 100% | β | ||
| fiercebiotech.com | 95% | 858.3K | #81,022 | View details | |
contagionlive.com | contagionlive.com | 74% | #501,198 | β | |
| cheetah-medical.com | 69% | View details | |||
vaccineindia.org | vaccineindia.org | 63% | β | ||
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 20 similar websites and full traffic analytics for Vaxart
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 20 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Vaxart (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vaxart
Complete news archive for Vaxart
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vaxart
Vaxart was founded in 2004 and raised its 1st funding round 3 years after it was founded.
Vaxart is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Vaxart is a funded company, having raised a total of $57.97M across 11 funding rounds to date. The company's 1st funding round was a Series A of $2.7M, raised on Apr 2007.
Vaxart has 115 employees.
Annual revenue of Vaxart is $237.26M as on Dec 31, 2025.
Founded in 2004 and based in San Francisco, United States, oral vaccines targeting infectious diseases are developed by Vaxart within the biotechnology sector. A proprietary delivery platform is employed to produce recombinant vaccines, with the pipeline covering seasonal influenza, norovirus, RSV, HSV-2, avian influenza, and Ebola. Vaccines addressing influenza treatment are also included in the offerings.
Vaxart's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Vaxart offers Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.
Yes, Vaxart is publicly traded on OTC under the ticker symbol VXRT.
Vaxart has 6 investors. Key investors include HHS, Care Capital Management, Care Capital, Quantum Technology Partners, and Life Science Angels.
Vaxart operates through Vaxart Inc..
